Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3426
Peer-review started: August 20, 2021
First decision: November 11, 2021
Revised: November 12, 2021
Accepted: February 27, 2022
Article in press: February 27, 2022
Published online: April 16, 2022
Processing time: 230 Days and 20.8 Hours
To reduce surgical pressure and accelerate postoperative functional recovery, enhanced recovery after surgery (ERAS) has been recommended. Although the application of biologics in treating inflammatory bowel disease has changed treatment strategies, most patients with inflammatory bowel disease (IBD) still require surgery.
Many patients with IBD require surgery. The motivation of this meta-analysis was to examine the effect of ERAS in IBD surgery.
The aim of this meta-analysis was to evaluate the advantage of ERAS in IBD surgery.
The PubMed, EMBASE and Cochrane Library databases were searched from inception to March 21, 2021 to find eligible studies. The primary outcome was the postoperative complications. The secondary outcomes included operation time, time to first flatus, time to bowel movement, postoperative hospital stay and readmission.
A total of eight studies involving 1939 patients were included in this meta-analysis. There was no difference in baseline information between the ERAS group and the non-ERAS group. No significant difference was found between the ERAS group and the non-ERAS group in terms of postoperative overall complications. The ERAS group had a lower prevalence of anastomotic fistula, less time to first flatus, less time to bowel movement and shorter postoperative hospital stays than the non-ERAS group.
ERAS was effective for the quicker recovery in IBD surgery and did not lead to increased complications.
This meta-analysis provided a preliminary conclusion on the effect of ERAS in IBD surgery. Therefore, multicenter, multiregional, prospective and high-quality randomized controlled trials should be carried out in the future.